These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 11139541)

  • 1. Charcoal treatment and risk of escape ovulation in oral contraceptive users.
    Elomaa K; Ranta S; Tuominen J; Lähteenmäki P
    Hum Reprod; 2001 Jan; 16(1):76-81. PubMed ID: 11139541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
    Elomaa K; Lähteenmäki P
    Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives.
    Elomaa K; Ranta S; Tuominen J; Lähteenmäki P
    Contraception; 2001 Jan; 63(1):13-8. PubMed ID: 11257243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene.
    Lüdicke F; Sullivan H; Spona J; Elstein M
    Contraception; 2001 Oct; 64(4):243-8. PubMed ID: 11747874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of ovulation by a new low-dose monophasic contraceptive containing gestodene.
    Thomas KH; Vankrieken L
    Int J Fertil; 1989 Sep; 34 Suppl():10-21. PubMed ID: 2576249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of endogenous hormones during one regular treatment cycle with a low-dose oral contraceptive and during two cycles with deliberate omission of two tablets.
    Endrikat J; Wessel J; Rosenbaum P; Düsterberg B
    Gynecol Endocrinol; 2004 Jun; 18(6):318-26. PubMed ID: 15497494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of planned in-vitro fertilization programming through the pre-administration of the oestrogen-progesterone combined pill.
    Cohen J; Debache C; Solal P; Serkine AM; Achard B; Boujenah A; Pez JP; Paris X; Robert J; Loffredo V
    Hum Reprod; 1987 Jan; 2(1):7-9. PubMed ID: 3106405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate.
    Rible RD; Taylor D; Wilson ML; Stanczyk FZ; Mishell DR
    Contraception; 2009 Mar; 79(3):182-8. PubMed ID: 19185670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of age on the response of the hypothalamo-pituitary-ovarian axis to a combined oral contraceptive.
    Fitzgerald C; Elstein M; Spona J
    Fertil Steril; 1999 Jun; 71(6):1079-84. PubMed ID: 10360914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial.
    Grimes DA; Godwin AJ; Rubin A; Smith JA; Lacarra M
    Obstet Gynecol; 1994 Jan; 83(1):29-34. PubMed ID: 8272303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting risk of ovulation in new start oral contraceptive users.
    Schwartz JL; Creinin MD; Pymar HC; Reid L
    Obstet Gynecol; 2002 Feb; 99(2):177-82. PubMed ID: 11814492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The suppression of ovarian function by the new oral contraceptive--Femodene.
    Stickland J; Tolowinska IY; Anthony F; Dennis KJ
    Contraception; 1987 May; 35(5):447-56. PubMed ID: 3621941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective multicentre study comparing levonorgestrel implants with a combined contraceptive pill: final results.
    Kirkman RJ; Bromham DR; O'Connor TP; Sahota JE
    Br J Fam Plann; 1999 Jul; 25(2):36-40. PubMed ID: 10454652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
    Hendrix CW; Jackson KA; Whitmore E; Guidos A; Kretzer R; Liss CM; Shah LP; Khoo KC; McLane J; Trapnell CB
    Clin Pharmacol Ther; 2004 May; 75(5):464-75. PubMed ID: 15116059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and biological justifications for the use of Triella].
    McGuire JL; Pasquale SA; Castaigne JP
    Rev Fr Gynecol Obstet; 1986 Dec; 81(12):731-6. PubMed ID: 3823727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraceptives.
    Maclennan AH
    Curr Ther (Seaforth); 1987 Dec; 28(12):113-22. PubMed ID: 12317413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.